Saturday, May 23, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Mr. David Levine, co-Chair of Co-Chair Science Writers in New York

We discuss the past, present, and future of healthcare journalism, gleaning lessons learned over the pandemic to predict upcoming trends.

Mr. Levine has had one of the most prolific and storied careers as a healthcare journalist, writing for organizations ranging from pharmaceutical behemoths to patient advocacy groups. During the pandemic, he actively combated vaccine misinformation through his writings and podcasts, and became a resource for many throughout the New York City healthcare system.

Science Writers in New York (SWINY) is composed of editors and writers who cover science and medicine in the print and electronic news media as well as public relations professionals who promote science.

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!